Novel stat3 inhibitors
US-2016068478-A1 · Mar 10, 2016 · US
Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9650399B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9650399-B2 |
| Application number | US-201314550293-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2013 |
| Priority date | May 25, 2012 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt, solvate or prodrug thereof. 2. The compound of claim 1 , wherein the compound is 3. The compound of claim 1 , wherein the compound is 4. The compound of claim 1 , wherein the compound is 5. The compound of claim 1 , wherein the compound is 6. A pharmaceutical composition comprising a compound as defined in claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an acceptable excipient. 7. A method for inhibiting STAT3 and/or STAT5 activity, comprising administering a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient. 8. A method for treating a cancer with cancer cells harbouring activated STAT3 or STAT5, comprising administering a therapeutically effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof to a patient, thereby inhibiting STAT3 or STATS. 9. The method of claim 8 , where said cancer is selected from solid or hematological tumors. 10. The method of claim 9 , wherein said cancer is selected from the group consisting of breast cancer, brain cancer, liver cancer, prostate cancer, pancreatic cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma, multiple myeloma, acute myelogenic leukemia (AML) and acute lymphoblastic leukemia. 11. A compound selected from the group consisting of: 12. A pharmaceutical composition comprising a compound as defined in claim 11 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an acceptable excipient. 13. A method for inhibiting STAT3 and/or STAT5 activity, comprising administering a therapeutically effective amount of a compound as defined in claim 11 or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient. 14. A method for treating a cancer with cancer cells harbouring activated STAT3 or STAT5, comprising administering a therapeutically effective amount of a compound as defined in claim 11 , or a pharmaceutically acceptable salt, solvate or prodrug thereof to a patient, thereby inhibiting STAT3 or STAT5. 15. The method of claim 14 , where said cancer is selected from solid or hematological tumors. 16. The method of claim 15 , wherein said cancer is selected from the group consisting of breast cancer, brain cancer, liver cancer, prostate cancer, pancreatic cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma, multiple myeloma, acute myelogenic leukemia (AML) and acute lymphoblastic leukemia.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Arylalkanephosphonic acids (C07F9/3839 takes precedence) · CPC title
to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9650399B2 cover?
- The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- Who is the assignee on this patent?
- Governing Council Univ Toronto, Uti Limited Partnership, Univ Indiana Res & Tech Corp
- What technology area does this patent fall under?
- Primary CPC classification C07F9/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).